IP Library Granted Patent US 12,349,882
Granted Patent B2
US 12,349,882 · App. 17/291,880 · Granted Jul 8, 2025

Dual check valve one handed applicator

Inventors: Paul J. Sanders (Greendale, WI); Krishnakumarsinh Hitendrasinh Parmar (Lisle, IL); Jerome Schafer (Liberty Township, OH)
Assignees: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
A61B17/00491A61B17/3498A61L24/104A61B2017/00407A61B2017/0042A61B2017/00495A61B2017/00884A61L2300/418A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,349,882
App. No.
17/291,880
Granted
Jul 8, 2025
Kind
B2
Abstract

Delivery devices, delivery systems, and related methods, for precise administration of hemostatic compositions are disclosed, which may include a trigger mechanism, a pusher, a valve, and a cannula. The pusher is configured to engage with the trigger mechanism, retain a first syringe, a least by coupling with a plunger of the first syringe. The valve is fluidly coupled to the first syringe. The valve is further configured to engage with a second syringe, in fluid communication with both the valve and the first syringe. The cannula extends distally from and is fluidly coupled to the valve. Activation of the trigger mechanism causes the pusher and the plunger of the first syringe to translate in a distal direction, to expel a composition out of the first syringe, through the valve, through the cannula, and out of a distal end of the cannula.

Claims (14)

1. A delivery device comprising:

a trigger mechanism;

a pusher, configured to engage with the trigger mechanism, the pusher further configured to retain a first syringe at least by coupling with a plunger of the first syringe;

a valve fluidly coupled to the first syringe; and

a cannula extending distally from and fluidly coupled to the valve, wherein the cannula includes an inner cannula configured to deliver a composition and an outer cannula, the outer cannula disposed concentrically around the inner cannula,

wherein activation of the trigger mechanism causes the pusher and the plunger of the first syringe to translate in a distal direction, such that the composition in the first syringe is expelled out of the first syringe, through the valve, through the inner cannula, and out of a distal end of the inner cannula, and

wherein the valve is further configured to engage with a second syringe, such that the second syringe is in fluid communication with both the valve and the first syringe, and

wherein the valve is a two-way check valve that permits a flow through a first flow path from the second syringe to the first syringe and a second flow path from the first syringe to the inner cannula,

wherein the composition is a viscous hemostatic material.

2. The delivery device of claim 1 , wherein prior to activation of the trigger mechanism, the composition is expelled out of the second syringe, through the valve, and into the first syringe, such that the first syringe is filled with the composition via the second syringe.

3. The delivery device of claim 1 , wherein engagement between the valve and the second syringe is a luer lock engagement.

4. The delivery device of claim 1 , wherein the pusher includes a plurality of teeth, and wherein the trigger mechanism includes a ratchet, the ratchet configured to engage with the plurality of teeth of the pusher.

5. The delivery device of claim 1 , further including a window indicator that indicates an amount of the composition remaining in the first syringe.

6. The delivery device of claim 1 , wherein the outer cannula is stainless steel.

Continuity (1)
Related Publication 20220015749A1 · Jan 20, 2022
References Cited (42)
US 6047861A · Vidal · 2000 [cited by examiner]
US 6079868A · Rydell · 2000 [cited by examiner]
US 20020077589A1 · Tessari · 2002 [cited by examiner]
US 20050092387A1 · Schorn et al. · 2005 [cited by applicant]
US 20080188843A1 · Appling et al. · 2008 [cited by applicant]
US 20080269720A1 · Sabbah · 2008 [cited by examiner]
US 20090247985A1 · Melsheimer · 2009 [cited by examiner]
US 20100310782A1 · Wawrzyniak · 2010 [cited by examiner]
US 20110319930A1 · Roush et al. · 2011 [cited by applicant]
US 20120065502A1 · Levy et al. · 2012 [cited by applicant]
US 20120143206A1 · Wallace et al. · 2012 [cited by applicant]
US 20130211374A1 · Hetherington · 2013 [cited by applicant]
US 20150025500A1 · Piehl et al. · 2015 [cited by applicant]
US 20150297207A1 · Maxwell et al. · 2015 [cited by applicant]
US 20160166761A1 · Piehl · 2016 [cited by examiner]
CA 2295249A1 · 2001 [cited by applicant]
CN 102958455A · 2013 [cited by applicant]
CN 103596619A · 2014 [cited by applicant]
CN 104159625A · 2014 [cited by applicant]
JP 2007530139A · 2007 [cited by applicant]
JP 2011104443A2 · 2011 [cited by applicant]
JP 2012161473A2 · 2015 [cited by applicant]
JP 5781597B2 · 2015 [cited by applicant]
JP 2017177073A2 · 2017 [cited by applicant]
WO 9944509A1 · 1999 [cited by applicant]
WO 2010129747A1 · 2010 [cited by applicant]
WO 2013098806A1 · 2013 [cited by applicant]
WO 2016138018A2 · 2016 [cited by applicant]
International Search Report for related International Application No. PCT/US2018/059628; action dated May 14, 2020; (6 pages). [cited by applicant]
Written Opinion for related International Application No. PCT/US2018/059628; action dated May 14, 2020; (10 pages). [cited by applicant]
Anonymous; “Floseal Instructions for Use”; Floseal Hemostatic Matrix; Apr. 6, 2015; http://www.floseal.com/int/pdf/FLOSEAL_IFU_EU.pdf. [cited by applicant]
Notice of Reasons for Refusal for Japanese Patent Application No. 2021-520571 dated Oct. 28, 2022. [cited by applicant]
Notification of First Office Action and English Translation from corresponding Chinese Patent Application No. 201880098795.0, dated Jan. 25, 2024. 17 pages. [cited by applicant]
Baxter Healthcare SA. (2015). Floseal Hemostatic Matrix 5ml/10ml: Instructions for Use (English). Zurich, Switzerland: Author. pp. 1-7. [cited by applicant]
Singaporean Written Opinion from corresponding Singaporean Patent Application No. 11202102248P, mailed Nov. 15, 2022. [cited by applicant]
Indian Examination Report from corresponding Indian Patent Application No. 202117017385, mailed Jan. 10, 2023. [cited by applicant]
International Preliminary Report on Patentability for related International Application No. PCT/US2018/059628; action dated May 20, 2021; (12 pages). [cited by applicant]
European Office Action from corresponding European Patent Application No. 18807525.3, mailed Sep. 6, 2023. 4 pages. [cited by applicant]
Korean Office Action from corresponding Korean Patent Application No. 10-2021-7016697, mailed Sep. 6, 2023. 6 pages. [cited by applicant]
Indian Examination Report from corresponding Indian Patent Application No. 202117017385, mailed Oct. 1, 2023. 5 pages. [cited by applicant]
Second Chinese Office Action for corresponding Chinese Patent Application No. 201880098795.0, dated Jul. 19, 2024. 6 pages. [cited by applicant]
Chinese Decision of Rejection from corresponding Chinese Patent Application No. 201880098795.0, dated Nov. 8, 2024. 19 pages. [cited by applicant]